Potential hepatitis C treatment may be as effective current standard treatment.
The Wall Street Journal (3/24, Kingsbury) reported that preliminary results from a midstage trial indicate that Zalbin (albinterferon alfa-2b) looks promising as a treatment for patients with genotypes 2 and 3 hepatitis C. In fact, Human Genome Sciences' monthly treatment appears to be just as effective as Roche Holding's Pegasys (peginterferon alfa-2a), according to Reuters (3/24, Dey).
The AP (3/24) pointed out that the "midstage study was conducted by Novartis, which is developing the drug with Human Genome Sciences. It combined the drug with ribavirin in 391 patients with forms of chronic hepatitis C." Notably, Human Genome "has submitted an application for Zalbin dosed every two weeks to the Food and Drug Administration, which is expected to make a decision this fall."
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment